CommentaryType 1 Diabetes

Evaluating Preclinical Efficacy

See allHide authors and affiliations

Science Translational Medicine  17 Aug 2011:
Vol. 3, Issue 96, pp. 96cm22
DOI: 10.1126/scitranslmed.3002757


Recent disappointing results of clinical trials seeking type 1 diabetes (T1D) reversal suggest the need for a reevaluation of our translational efforts. This Commentary explores the need for standards in evaluating therapeutic efficacy in preclinical models of T1D.


  • Citation: M. A. Atkinson, Evaluating preclinical efficacy. Sci. Transl. Med. 3, 96cm22 (2011).

View Full Text

Stay Connected to Science Translational Medicine